ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
This early phase I trial tests the safety and side effects of ZN-c3 in treating patients with
triple-negative breast cancer or ovarian cancer that have spread to other parts of the body
(metastatic or advanced). ZN-c3 is an enzyme inhibitor that may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth.